SEC Form 8-K: Press Release dated December 19, 2024

BPTH_20241219_8-K

Bio-Path Holdings Announces Preclinical Testing of BP1001-A as  Potential Treatment for Obesity in Type 2 Diabetes Patients Enhances Insulin Sensitivity

BP1001-A_Obesity_Initial_Efficacy_Testing

SEC Form 8-K: Other Items

BPTH_24-31094-1_D1.2_20241213Download

SEC Form 8-K: Press Release dated December 11, 2024

BPTH_20241212_8-K

Bio-Path Holdings Outlines Rationale for Development of BP1001-A as Potential Treatment for Obesity in Type 2 Diabetes Patients

BP1001-A_Scientific_Rationale_Press_Release

SEC Form 8-K: Other Events

BPTH_8-K_20241125

SEC Form 8-K: Press Release dated November 15, 2024

BPTH20241115_8-K

Bio-Path Holdings Reports Third Quarter 2024 Financial Results

BPTH_Third_Quarter_2024_Earnings_Release

SEC Form 10-Q: For Period ending September 30, 2024

BPTH_20241114_10-Q

Bio-Path Holdings to Announce Third Quarter 2024 Financial Results on November 15, 2024

BPTH_Third_Quarter_2024_Earnings_Announcement